Executive Coaching is designed as a thought-provoking and creative process that inspires leaders to maximize their personal and professional potential. At TLD Group we take our commitment to this philosophy seriously. As a health ecosystem talent development firm, we have designed our coaching solutions specifically with health industry leaders in mind.
May is Mental Health Awareness Month and The Leadership Development Group (TLD Group) took an opportunity to interview Laura Marsh, MD, Executive Director, Mental Health Care Line for the Veteran Affairs Medical Center in Houston, TX. Dr. Marsh, a geriatric psychiatrist and a neuropsychiatrist whose background is in neurological conditions with psychiatric complications, is also Professor, Menninger Department of Psychiatry, Baylor College of Medicine in Houston.
In this blog, Dr. Marsh shares her recommendations for leaders looking to move the needle on mental health initiatives within their own communities. Below is a preview of the longer interview.
We are fortunate to have an advisory board, comprised of multi-sector industry leaders from a variety of disciplines, to guide our strategy and growth. We have created the “Meet the Advisory Board” series as a way to introduce you to these talented leaders and learn about their perspectives on leadership and cross-sector collaboration.
In this interview meet Advisory Board member Kent Bottles, MD. Kent is our resident futurist and a thought-leader in healthcare policy and payment reform. At TLD Group we turn to him often for his perspective on health industry transformation and change.
Interview with TLD Group Advisory Board Member- Kent Bottles
We are fortunate to have an advisory board, comprised of multi-sector industry leaders from a variety of disciplines, to guide our strategy and growth. We have created the “Meet the Advisory Board” series as a way to introduce you to these talented leaders and learn about their perspectives on leadership and cross-sector collaboration.
In this inaugural interview meet Advisory Board Chair Bob Sachs, PhD. Bob has a passion for leadership development and offers timely advice for today's leaders.
Interview with TLD Group Advisory Board Chair- Bob Sachs
Pre-COVID, many of us viewed our primary care, specialist or hospital-based physicians as trusted and skilled professionals in their crisp white coats with the embroidered logos of their practices or larger, parent health system.
As a firm, we strongly support the notion that diverse leadership is critical for organizational success. A discrepancy between the prevalence of women in the pipeline and absence of equal representation in advanced leadership roles, highlights the need for organizations to correct the strategic, structural, and cultural components which impact diversity, inclusion, and equity.
As a firm, we strongly support the notion that diverse leadership is critical for organizational success. A discrepancy between the prevalence of women in the pipeline and absence of equal representation in advanced leadership roles, highlights the need for organizations to correct the strategic, structural, and cultural components which impact diversity, inclusion, and equity.
As a firm, we strongly support the notion that diverse leadership is critical for organizational success. A discrepancy between the prevalence of women in the pipeline and absence of equal representation in advanced leadership roles, highlights the need for organizations to correct the strategic, structural, and cultural components which impact diversity, inclusion, and equity.
As a firm, we strongly support the notion that diverse leadership is critical for organizational success. A discrepancy between the prevalence of women in the pipeline and absence of equal representation in advanced leadership roles, highlights the need for organizations to correct the strategic, structural, and cultural components which impact diversity, inclusion, and equity.
Before the World Health Organization (WHO) declared COVID-19 a pandemic, pharmaceutical companies like Pfizer, Moderna, Johnson & Johnson and Gilead were often tagged as “big pharma” putting profit before purpose.
Now, one year later, pharmaceutical companies are being praised for their positive impact resulting from the speed at which they were capable of producing FDA-approved treatments and vaccines for COVID-19.
Through its ingenuity, strategic leadership and nimble pipeline management practices, the pharmaceutical industry is meeting a deep and drastic human need: to keep ourselves and our loved ones healthy and alive.
